184 related articles for article (PubMed ID: 24596380)
1. Correlation of Wilms' tumor 1 isoforms with HER2 and ER-α and its oncogenic role in breast cancer.
Nasomyon T; Samphao S; Sangkhathat S; Mahattanobon S; Graidist P
Anticancer Res; 2014 Mar; 34(3):1333-42. PubMed ID: 24596380
[TBL] [Abstract][Full Text] [Related]
2. Wilms' tumor gene WT1 17AA(-)/KTS(-) isoform induces morphological changes and promotes cell migration and invasion in vitro.
Jomgeow T; Oji Y; Tsuji N; Ikeda Y; Ito K; Tsuda A; Nakazawa T; Tatsumi N; Sakaguchi N; Takashima S; Shirakata T; Nishida S; Hosen N; Kawakami M; Tsuboi A; Oka Y; Itoh K; Sugiyama H
Cancer Sci; 2006 Apr; 97(4):259-70. PubMed ID: 16630117
[TBL] [Abstract][Full Text] [Related]
3. The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
Reizner N; Maor S; Sarfstein R; Abramovitch S; Welshons WV; Curran EM; Lee AV; Werner H
J Mol Endocrinol; 2005 Aug; 35(1):135-44. PubMed ID: 16087727
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor I regulates the expression of isoforms of Wilms' tumor 1 gene in breast cancer.
Tuna M; Itamochi H
Tumori; 2013; 99(6):715-22. PubMed ID: 24503796
[TBL] [Abstract][Full Text] [Related]
5. The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance.
Wang L; Zhang X; Wang ZY
Anticancer Res; 2010 Sep; 30(9):3637-42. PubMed ID: 20944147
[TBL] [Abstract][Full Text] [Related]
6. The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.
Wang L; Wang ZY
Oncol Rep; 2010 Apr; 23(4):1109-17. PubMed ID: 20204298
[TBL] [Abstract][Full Text] [Related]
7. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of the human thromboxane A2 receptor gene by Wilms' tumor (WT)1 and hypermethylated in cancer (HIC) 1 in prostate and breast cancers.
Keating GL; Reid HM; Eivers SB; Mulvaney EP; Kinsella BT
Biochim Biophys Acta; 2014 Jun; 1839(6):476-92. PubMed ID: 24747176
[TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor gene WT1 promotes homologous recombination-mediated DNA damage repair.
Oji Y; Tatsumi N; Kobayashi J; Fukuda M; Ueda T; Nakano E; Saito C; Shibata S; Sumikawa M; Fukushima H; Saito A; Hojo N; Suzuki M; Hoshikawa T; Shimura T; Morii E; Oka Y; Hosen N; Komatsu K; Sugiyama H
Mol Carcinog; 2015 Dec; 54(12):1758-71. PubMed ID: 25418835
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.
He Q; Peng B; Zhuang D; Xiao L; Zheng L; Fan Z; Zhu J; Xu B; Xu C; Zhao J; Wu L; Zhou P; Hou L; Yu F; Zhao G
Cancer Biomark; 2015; 15(6):823-31. PubMed ID: 26406408
[TBL] [Abstract][Full Text] [Related]
11. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
12. WT1 promotes invasion of NSCLC via suppression of CDH1.
Wu C; Zhu W; Qian J; He S; Wu C; Chen Y; Shu Y
J Thorac Oncol; 2013 Sep; 8(9):1163-9. PubMed ID: 23945386
[TBL] [Abstract][Full Text] [Related]
13. The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.
Bourkoula K; Englert C; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2014 Jan; 134(2):291-300. PubMed ID: 23832418
[TBL] [Abstract][Full Text] [Related]
14. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
[TBL] [Abstract][Full Text] [Related]
15. The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.
Bissanum R; Lirdprapamongkol K; Svasti J; Navakanitworakul R; Kanokwiroon K
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):256-262. PubMed ID: 29024629
[TBL] [Abstract][Full Text] [Related]
16. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
17. Expression of estrogen receptor beta isoforms in human breast cancer tissues and cell lines.
Tong D; Schuster E; Seifert M; Czerwenka K; Leodolte S; Zeillinger R
Breast Cancer Res Treat; 2002 Feb; 71(3):249-55. PubMed ID: 12002343
[TBL] [Abstract][Full Text] [Related]
18. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
Zhang X; Deng H; Wang ZY
J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1.
Xie F; Hosany S; Zhong S; Jiang Y; Zhang F; Lin L; Wang X; Gao S; Hu X
PLoS One; 2017; 12(10):e0185565. PubMed ID: 29016617
[TBL] [Abstract][Full Text] [Related]
20. The mTOR inhibitor rapamycin synergizes with a fatty acid synthase inhibitor to induce cytotoxicity in ER/HER2-positive breast cancer cells.
Yan C; Wei H; Minjuan Z; Yan X; Jingyue Y; Wenchao L; Sheng H
PLoS One; 2014; 9(5):e97697. PubMed ID: 24866893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
